Baliforsen

Drug Profile

Baliforsen

Alternative Names: BIIB 065; IONIS-DMPK-2.5Rx; ISIS 598769; ISIS DMPKRx; ISIS-DMPK-2.5Rx

Latest Information Update: 15 Nov 2016

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Ionis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myotonic dystrophy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Myotonic dystrophy

Most Recent Events

  • 01 Aug 2016 Ionis Pharmaceuticals completes a phase-I/II clinical trial in Myotonic dystrophy in USA (SC) (NCT02312011)
  • 15 Jun 2016 Phase-II clinical trials in Myotonic dystrophy in USA (SC) (Ionis Pharmaceuticals pipeline, June 2016)
  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top